Information  X 
Enter a valid email address

Oxford BioDynamics (OBD)

  Print      Mail a friend

Friday 25 January, 2019

Oxford BioDynamics

Publication of Annual Report and Notice of AGM

RNS Number : 0718O
Oxford BioDynamics PLC
25 January 2019
 

25 January 2019

 

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

Publication of 2018 Annual Report and Accounts and Notice of AGM

 

Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, announces that copies of its annual report and accounts for the year ended 30 September 2018 (incorporating the Notice of Annual General Meeting) ("Annual Report") will be posted to shareholders today. An electronic copy of the Annual Report will be available on its website at www.oxfordbiodynamics.com, within the Investor Relations section.

 

Notice of Annual General Meeting

The Company's Annual General Meeting will be held at The Linbury Room, Worcester College, Oxford, OX1 2HB on 14 March 2019 at 11.00 am.

 

 

-ENDS-

 

For further details please contact:

 

Oxford BioDynamics Plc

Christian Hoyer Millar, CEO

Paul Stockdale, CFO

 

+44 (0)1865 518910

Shore Capital

Nominated Advisor and Broker

Stephane Auton

Edward Mansfield

+44 (0)20 7408 4090

 

FTI Consulting

Financial Public Relations Adviser

Brett Pollard

Natalie Garland-Collins

 

+44 (0)20 3727 1000

 

Notes for Editors

 

About Oxford BioDynamics Plc

 

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

 

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

 

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DOCLFFSFLIISFIA

a d v e r t i s e m e n t